Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. Consequently, there was an increase in the notional allocation of Ordinary Share ADRs on July 29, 2005, at a price of $47.44 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items beyond the specific transaction notification. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of the individual involved in the transaction: Russell Greig.
- Confirm the transaction date (July 29, 2005) and the notification date (August 2, 2005).
- Validate the share price of $47.44 per share used for the notional allocation increase.
- Review the specific terms of the US Retirement Savings Plan regarding notional ADR holdings.